Literature DB >> 20977290

A biorelevant dissolution stress test device - background and experiences.

Grzegorz Garbacz1, Sandra Klein, Werner Weitschies.   

Abstract

IMPORTANCE OF THE FIELD: The prediction of the in vivo drug release characteristics of modified release (MR) oral dosage forms by in vitro dissolution tests is a prerequisite for successful product development. AREAS COVERED IN THIS REVIEW: To improve the predictive power of dissolution testing, the authors recently developed a new dissolution test apparatus that simulates physical conditions of the gastrointestinal (GI) passage of MR dosage forms. The simulation includes pressure force exerted by GI motility, shear stress force generated during phases of GI transport and intermittent contact with intestinal fluids while the dosage form is located in an intestinal air pocket. WHAT THE READER WILL GAIN: The article briefly describes selected aspects of GI tract physiology, evolution and goals of dissolution testing as well as the development and use of test devices that are intended to simulate GI tract conditions. The data are discussed in the light of the test results obtained with the new dissolution stress test device developed by the authors' group. Achievements reported from 1986 to 2010 are referred to. TAKE HOME MESSAGE: The new apparatus was evaluated using extended release (ER) tablets of nifedipine and diclofenac. The dissolution characteristics of some of the tested products were strongly dependent on the test conditions and could be distinctly influenced by the mechanical stress events of biorelevant intensity. Results of these experiments thus indicated that a high sensitivity of dosage forms to GI-specific physical conditions has to be regarded as a major cause of irregularities in the drug release profiles, which may result in fluctuations of the individual drug plasma concentration profiles, as, for example, caused by dose dumping.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20977290     DOI: 10.1517/17425247.2010.527943

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  9 in total

1.  A semi-mechanistic modeling strategy to link in vitro and in vivo drug release for modified release formulations.

Authors:  Martin Bergstrand; Erik Söderlind; Ulf G Eriksson; Werner Weitschies; Mats O Karlsson
Journal:  Pharm Res       Date:  2011-09-27       Impact factor: 4.200

2.  Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications.

Authors:  Feng Qian; Jennifer Wang; Ruiling Hartley; Jing Tao; Raja Haddadin; Neil Mathias; Munir Hussain
Journal:  Pharm Res       Date:  2012-10       Impact factor: 4.200

3.  The improvement of the dissolution rate of ziprasidone free base from solid oral formulations.

Authors:  Daniel Zakowiecki; Krzysztof Cal; Kamil Kaminski; Karolina Adrjanowicz; Lech Swinder; Ewa Kaminska; Grzegorz Garbacz
Journal:  AAPS PharmSciTech       Date:  2015-01-16       Impact factor: 3.246

4.  Release characteristics of quetiapine fumarate extended release tablets under biorelevant stress test conditions.

Authors:  Grzegorz Garbacz; Anna Kandzi; Mirko Koziolek; Jarosław Mazgalski; Werner Weitschies
Journal:  AAPS PharmSciTech       Date:  2013-12-03       Impact factor: 3.246

Review 5.  In Vitro and In Vivo Test Methods for the Evaluation of Gastroretentive Dosage Forms.

Authors:  Felix Schneider; Mirko Koziolek; Werner Weitschies
Journal:  Pharmaceutics       Date:  2019-08-16       Impact factor: 6.321

6.  Biorelevant In Vitro Release Testing and In Vivo Study of Extended-Release Niacin Hydrophilic Matrix Tablets.

Authors:  Bartłomiej Milanowski; Arkadiusz Hejduk; Marek A Bawiec; Emilia Jakubowska; Agnieszka Urbańska; Anna Wiśniewska; Grzegorz Garbacz; Janina Lulek
Journal:  AAPS PharmSciTech       Date:  2020-01-27       Impact factor: 3.246

7.  Comparison of In Vitro and In Vivo Results Using the GastroDuo and the Salivary Tracer Technique: Immediate Release Dosage Forms under Fasting Conditions.

Authors:  Maximilian Sager; Philipp Schick; Magdalena Mischek; Christian Schulze; Mahmoud Hasan; Marie-Luise Kromrey; Hassan Benameur; Martin Wendler; Mladen Vassilev Tzvetkov; Werner Weitschies; Mirko Koziolek
Journal:  Pharmaceutics       Date:  2019-12-07       Impact factor: 6.321

8.  Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial.

Authors:  Ewelina Juszczyk; Kamil Kisło; Paweł Żero; Ewa Tratkiewicz; Maciej Wieczorek; Jadwiga Paszkowska; Grzegorz Banach; Marcela Wiater; Dagmara Hoc; Grzegorz Garbacz; Jaroslaw Sczodrok; Dorota Danielak
Journal:  Pharmaceutics       Date:  2021-05-28       Impact factor: 6.321

9.  IVIVC for Extended Release Hydrophilic Matrix Tablets in Consideration of Biorelevant Mechanical Stress.

Authors:  Valentyn Mohylyuk; Seyedreza Goldoozian; Gavin P Andrews; Andriy Dashevskiy
Journal:  Pharm Res       Date:  2020-10-22       Impact factor: 4.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.